Ukwelashwa Okusha Okuhlanganisiwe Kwezinkinga Ezibangelwa Isifo Sikashukela ze-Cornea

A BAMBA Ukukhululwa Kwamahhala | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-RegeneRx Biopharmaceuticals, Inc. ibika ukuthi abacwaningi babonise ukuphumelela kokwelapha kwe-Thymosin Beta 4 (Tβ4) njengokwelashwa okuhlangene ngokumelene nezinguquko ze-hyperglycemia (isifo sikashukela) -ezibangelwa amaseli e-corneal epithelial.

“Ucwaningo lwethu lucacisa okokuqala ngqa ukuthi ukwelashwa kwenhlanganisela ye-Tβ4 kanye ne-vasoactive intestinal peptide (VIP) kudlala indima ebalulekile ekulawuleni ukuqina kwe-tight junction kanye nokuhlelwa kabusha kwe-cytoskeleton [ye-cornea], okuhlobene eduze nobuqotho besithiyo. Ngaphezu kwalokho, i-Tβ4 isungula ngokuqinile indima yayo njengokwelashwa okungeziwe kwezithiyo ze-corneal yesifo sikashukela ngaphandle kwemiphumela emibi, ngaleyo ndlela kudambise ukonakala kwezindlela zamanje zokunakekelwa [kweso],” ngokusho kwethimba locwaningo.

Ucwaningo lwethulwe emhlanganweni we-Association for Research in Vision and Ophthalmology (ARVO) 2022, owawubanjwe ngoMeyi 1-4, 2022, eDenver, Colorado. Ithimba locwaningo lalihlanganisa ososayensi nodokotela baseWayne State University School of Medicine eDetroit, MI; i-University of Central Florida College of Health Professors and Sciences e-Orlando, FL; kanye neNyuvesi yaseMansoura eMansoura, eGibhithe. Lolu cwaningo luxhaswe yiNational Institutes of Health, i-Eversight Centre for Vision and Eye Banking Research, kanye ne-Research to Prevent Blindness.

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...